Asia Microbiota Bank

Asia Microbiota Bank (AMB) is a Hong Kong-based biotechnology company and the first commercial stool bank in Asia dedicated to providing safe and standardized fecal microbiota transplant (FMT) materials. The company focuses on the screening, processing, and storage of high-quality donor microbiota to treat recurrent Clostridioides difficile infections and support clinical research into microbiome-based therapies. AMB collaborates extensively with academic institutions, particularly the Chinese University of Hong Kong (CUHK), to explore the role of the gut microbiome in inflammatory bowel disease, metabolic disorders, and autoimmune conditions. Their services include donor recruitment, rigorous health screening, and the production of FMT preparations for clinical use. By providing a centralized resource for microbiota, AMB aims to increase the accessibility and safety of FMT procedures across the Asia-Pacific region.